Properties (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associatedWith |
gptkb:West_Nile_fever
neuroinvasive disease |
| gptkbp:availability |
commercially available
|
| gptkbp:clinicalTrials |
ongoing research
|
| gptkbp:contraindication |
severe allergic reactions
rare neurological disorders |
| gptkbp:developedBy |
various pharmaceutical companies
|
| gptkbp:dosageForm |
single dose for horses
two doses for humans |
| gptkbp:evaluates |
approximately 90% in horses
|
| gptkbp:funding |
government grants
private investments |
| gptkbp:future_plans |
annual vaccination for horses
pre-season vaccination for humans |
| gptkbp:geographicalFeature |
available in multiple countries
|
| https://www.w3.org/2000/01/rdf-schema#label |
West Nile virus vaccines
|
| gptkbp:impact |
decreased mortality rates
reduced_incidence_of_West_Nile_virus |
| gptkbp:is_essential_for |
public health measure
|
| gptkbp:is_monitored_by |
post-marketing surveillance
|
| gptkbp:issuedBy |
injection
|
| gptkbp:lastProduced |
2003
|
| gptkbp:manufacturer |
gptkb:Merck
gptkb:Boehringer_Ingelheim Zoetis |
| gptkbp:marketedAs |
various brand names
|
| gptkbp:notable_player |
DNA vaccine
new delivery methods ongoing innovations subunit vaccine recombinant vaccine combination vaccines |
| gptkbp:publicAccess |
educational campaigns
|
| gptkbp:regulatoryCompliance |
varies by country
|
| gptkbp:researchFocus |
improving efficacy
reducing side effects developing new formulations |
| gptkbp:researchInterest |
various universities
government health agencies |
| gptkbp:sideEffect |
fatigue
mild fever swelling at injection site |
| gptkbp:storage |
refrigerated
|
| gptkbp:suitableFor |
at-risk populations
|
| gptkbp:targets |
gptkb:West_Nile_virus
equines humans at risk |
| gptkbp:type |
live attenuated vaccine
inactivated virus vaccine |
| gptkbp:usedIn |
humans
horses |